Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

The company made an even more dramatic claim the following month, when it announced it had created three dire wolves. These ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

Carvykti sales surge, MRD FDA guidance speeds label expansion, and strong cash runway. Click for more on LEGN stock.

While GLP-1 (glucagon-like peptide-1) class obesity treatments like ‘Wegovy’ and ‘Mounjaro’ have gained immense popularity, ...

Long-term data suggest Moderna’s personalized melanoma shot provides “durable tumor control,” one analyst said. Elsewhere, ...

Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...

Local biotech entrepreneurs and investors are seeing signs that the four-year "biotech winter" is finally thawing, though ...

At some point in your research career, you may find yourself transitioning from academia to industry or vice versa. To best set yourself up for success, adapt your approach to the specific scientific ...